Rewriting the Rules of Mitral Valve Repair
Nyra Medical is redefining transcatheter repair for functional (secondary) mitral regurgitation with the Cardiac Leaflet Enhancer (CARLEN) — a single-leaflet solution designed to preserve native valve function and expand treatment options for both TEER-eligible patients and those historically left behind.
Expanding Access to Life-Changing Mitral Repair
CARLEN is a dynamic leaflet augmenting technology, designed to be delivered onto either the anterior or posterior leaflet of the mitral valve using image guidance, which is intended to correct FMR by providing additional length and thickness to the leaflet at the site of the regurgitation.
Founded to Redefine Mitral Valve Repair
Nyra Medical was founded in 2019, based on intellectual property developed at Emory University by Dr. Murali Padala. The company licensed its core technology, CARLEN, in 2021 and raised Series A in 2022 supported by experienced medtech investors. In 2023, industry veteran Lori Chmura joined as CEO to lead Nyra Medical through First-in-Human studies and global clinical research.
